{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:06:59Z","timestamp":1794024419139,"version":"4.8.0"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T00:00:00Z","timestamp":1691452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Celltrion Healthcare South Korea"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Anti-tumour necrosis factor [TNF] treatment failure in patients with inflammatory bowel disease [IBD] is common and frequently related to low drug concentrations. In order to identify patients who may benefit from dose optimisation at the outset of anti-TNF therapy, we sought to define epigenetic biomarkers in whole blood at baseline associated with anti-TNF drug concentrations at week 14.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>DNA methylation from 1104 whole blood samples from 385 patients in the Personalised Anti-TNF Therapy in Crohn\u2019s disease [PANTS] study were assessed using the Illumina EPIC Beadchip [v1.0] at baseline and weeks 14, 30, and 54. We compared DNA methylation profiles in anti-TNF-treated patients who experienced primary non-response at week 14 if they were assessed at subsequent time points and were not in remission at week 30 or 54 [infliximab n = 99, adalimumab n = 94], with patients who responded at week 14 and when assessed at subsequent time points were in remission at week 30 or 54 [infliximab n = 99, adalimumab n = 93].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, between baseline and week 14, we observed 4999 differentially methylated positions [DMPs] annotated to 2376 genes following anti-TNF treatment. Pathway analysis identified 108 significant gene ontology terms enriched in biological processes related to immune system processes and responses. Epigenome-wide association [EWAS] analysis identified 323 DMPs annotated to 210 genes at baseline associated with higher anti-TNF drug concentrations at Week 14. Of these, 125 DMPs demonstrated shared associations with other common traits [proportion of shared CpGs compared with DMPs] including body mass index [23.2%], followed by C-reactive protein [CRP] [11.5%], smoking [7.4%], alcohol consumption per day [7.1%], and IBD type [6.8%]. EWAS of primary non-response to anti-TNF identified 20 DMPs that were associated with both anti-TNF drug concentration and primary non-response to anti-TNF with a strong correlation of the coefficients [Spearman\u2019s rho = -0.94, p &amp;lt;0.001].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Baseline DNA methylation profiles may be used as a predictor for anti-TNF drug concentration at week 14 to identify patients who may benefit from dose optimisation at the outset of anti-TNF therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjad133","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T08:02:44Z","timestamp":1691395364000},"page":"1190-1201","source":"Crossref","is-referenced-by-count":20,"title":["Whole Blood DNA Methylation Changes Are Associated with Anti-TNF Drug Concentration in Patients with Crohn\u2019s Disease"],"prefix":"10.1093","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4201-4879","authenticated-orcid":false,"given":"Simeng","family":"Lin","sequence":"first","affiliation":[{"name":"Gastroenterology, Royal Devon University Healthcare NHS Foundation Trust , Exeter , UK"},{"name":"Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter , Exeter , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6840-072X","authenticated-orcid":false,"given":"Eilis","family":"Hannon","sequence":"additional","affiliation":[{"name":"University of Exeter Medical School, Faculty of Health and Life Sciences, University of Exeter , Exeter , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7992-4537","authenticated-orcid":false,"given":"Mark","family":"Reppell","sequence":"additional","affiliation":[{"name":"Precision Medicine Immunology, AbbVie Inc., Chicago , IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey F","family":"Waring","sequence":"additional","affiliation":[{"name":"Precision Medicine Immunology, AbbVie Inc., Chicago , IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar","family":"Smaoui","sequence":"additional","affiliation":[{"name":"Precision Medicine Immunology, AbbVie Inc., Chicago , IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6647-8494","authenticated-orcid":false,"given":"Valerie","family":"Pivorunas","sequence":"additional","affiliation":[{"name":"Precision Medicine Immunology, AbbVie Inc., Chicago , IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6754-9589","authenticated-orcid":false,"given":"Heath","family":"Guay","sequence":"additional","affiliation":[{"name":"Precision Medicine Immunology, AbbVie Inc., Chicago , IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0207-6706","authenticated-orcid":false,"given":"Neil","family":"Chanchlani","sequence":"additional","affiliation":[{"name":"Gastroenterology, Royal Devon University Healthcare NHS Foundation Trust , Exeter , UK"},{"name":"Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter , Exeter , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0965-9587","authenticated-orcid":false,"given":"Claire","family":"Bewshea","sequence":"additional","affiliation":[{"name":"Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter , Exeter , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0765-6398","authenticated-orcid":false,"given":"Benjamin Y H","family":"Bai","sequence":"additional","affiliation":[{"name":"Genomics of Inflammation and Immunity Group, Wellcome Sanger Institute , Hinxton , UK"},{"name":"Postgraduate School of Life Sciences, University of Cambridge , Cambridge , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4368-1961","authenticated-orcid":false,"given":"Nicholas A","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Gastroenterology, Royal Devon University Healthcare NHS Foundation Trust , Exeter , UK"},{"name":"Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter , Exeter , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3112-376X","authenticated-orcid":false,"given":"James R","family":"Goodhand","sequence":"additional","affiliation":[{"name":"Gastroenterology, Royal Devon University Healthcare NHS Foundation Trust , Exeter , UK"},{"name":"Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter , Exeter , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1115-3224","authenticated-orcid":false,"given":"Jonathan","family":"Mill","sequence":"additional","affiliation":[{"name":"University of Exeter Medical School, Faculty of Health and Life Sciences, University of Exeter , Exeter , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6058-5528","authenticated-orcid":false,"given":"Tariq","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Gastroenterology, Royal Devon University Healthcare NHS Foundation Trust , Exeter , UK"},{"name":"Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter , Exeter , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,8]]},"reference":[{"key":"2024082420333491900_CIT0001","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S2468-1253(21)00312-5","article-title":"Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn\u2019s disease: a systematic review and network meta-analysis","volume":"6","author":"Singh","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024082420333491900_CIT0002","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/gutjnl-2022-328052","article-title":"Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn\u2019s disease: systematic review and network meta-analysis","volume":"72","author":"Barberio","year":"2022","journal-title":"Gut"},{"key":"2024082420333491900_CIT0003","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/apt.13847","article-title":"Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn\u2019s disease and ulcerative colitis","volume":"45","author":"Mao","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2024082420333491900_CIT0004","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/MIB.0000000000000202","article-title":"Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse","volume":"21","author":"Papamichael","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"2024082420333491900_CIT0005","first-page":"1","article-title":"Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn\u2019s disease: a prospective, multicentre, cohort study","volume":"1253","author":"Kennedy","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024082420333491900_CIT0006","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1053\/j.gastro.2019.09.041","article-title":"HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn\u2019s disease","volume":"158","author":"Sazonovs","year":"2020","journal-title":"Gastroenterology"},{"key":"2024082420333491900_CIT0007","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/ibd\/izab285","article-title":"Dashboard-driven accelerated infliximab induction dosing increases infliximab durability and reduces immunogenicity","volume":"28","author":"Dubinsky","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"2024082420333491900_CIT0008","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/MPG.0000000000003587","article-title":"Optimized infliximab induction predicts better long-term clinical and biomarker outcomes compared with standard induction dosing","volume":"75","author":"Lawrence","year":"2022","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2024082420333491900_CIT0009","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nm.4307","article-title":"Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease","volume":"23","author":"West","year":"2017","journal-title":"Nat Med"},{"key":"2024082420333491900_CIT0010","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1093\/ibd\/izab032","article-title":"Oncostatin M is a biomarker of diagnosis, worse disease prognosis, and therapeutic nonresponse in inflammatory bowel disease","volume":"27","author":"Verstockt","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2024082420333491900_CIT0011","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1136\/gutjnl-2017-315494","article-title":"Cell-centred meta-analysis reveals baseline predictors of anti-TNF\u03b1 non-response in biopsy and blood of patients with IBD","volume":"68","author":"Gaujoux","year":"2019","journal-title":"Gut"},{"key":"2024082420333491900_CIT0012","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ebiom.2019.01.027","article-title":"Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease","volume":"40","author":"Verstockt","year":"2019","journal-title":"EBioMed"},{"key":"2024082420333491900_CIT0013","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1093\/ecco-jcc\/jjac027","article-title":"Tailoring multi-omics to inflammatory bowel diseases: all for one and one for all","volume":"16","author":"Sudhakar","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2024082420333491900_CIT0014","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/ecco-jcc\/jjab050","article-title":"Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD\u2014Disease Outcome and Response to Therapy","volume":"15","author":"Verstockt","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2024082420333491900_CIT0015","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(18)31268-6","article-title":"Principles of DNA methylation and their implications for biology and medicine","volume":"392","author":"Dor","year":"2018","journal-title":"Lancet"},{"key":"2024082420333491900_CIT0016","first-page":"321","article-title":"Function and information content of DNA methylation","volume-title":"Nature","author":"Sch\u00fcbeler","year":"2015"},{"key":"2024082420333491900_CIT0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12864-015-1271-4","article-title":"Characterization of tissue-specific differential DNA methylation suggests distinct modes of positive and negative gene expression regulation","volume":"16","author":"Wan","year":"2015","journal-title":"BMC Genomics"},{"key":"2024082420333491900_CIT0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13059-022-02728-5","article-title":"Large-scale manipulation of promoter DNA methylation reveals context-specific transcriptional responses and stability","volume":"23","author":"de Mendoza","year":"2022","journal-title":"Genome Biol"},{"key":"2024082420333491900_CIT0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13059-021-02347-6","article-title":"Genetic impacts on DNA methylation: research findings and future perspectives","volume":"22","author":"Villica\u00f1a","year":"2021","journal-title":"Genome Biol"},{"key":"2024082420333491900_CIT0020","doi-asserted-by":"crossref","first-page":"e1007544","DOI":"10.1371\/journal.pgen.1007544","article-title":"Characterizing genetic and environmental influences on variable DNA methylation using monozygotic and dizygotic twins","volume":"14","author":"Hannon","year":"2018","journal-title":"PLoS Genet"},{"key":"2024082420333491900_CIT0021","doi-asserted-by":"crossref","first-page":"R115","DOI":"10.1186\/gb-2013-14-10-r115","article-title":"DNA methylation age of human tissues and cell types","volume":"14","author":"Horvath","year":"2013","journal-title":"Genome Biol"},{"key":"2024082420333491900_CIT0022","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.crohns.2014.02.002","article-title":"Smoking in inflammatory bowel disease: Impact on disease course and insights into the aetiology of its effect","volume":"8","author":"Parkes","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2024082420333491900_CIT0023","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nrg3000","article-title":"Epigenome-Wide Association Studies for common human diseases","volume":"12","author":"Rakyan","year":"2011","journal-title":"Nat Rev Genet"},{"key":"2024082420333491900_CIT0024","doi-asserted-by":"crossref","first-page":"e1006105","DOI":"10.1371\/journal.pgen.1006105","article-title":"Epigenome-wide Association Studies and the Interpretation of Disease: Omics","volume":"12","author":"Birney","year":"2016","journal-title":"PLOS Genet"},{"key":"2024082420333491900_CIT0025","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/ecco-jcc\/jjv176","article-title":"DNA methylation profiling in inflammatory bowel disease provides new insights into disease pathogenesis","volume":"10","author":"McDermott","year":"2016","journal-title":"J Crohns Colitis"},{"key":"2024082420333491900_CIT0026","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1053\/j.gastro.2019.01.270","article-title":"Blood-Derived DNA Methylation Signatures of Crohn\u2019s Disease and Severity of Intestinal Inflammation","volume":"156","author":"Somineni","year":"2019","journal-title":"Gastroenterology"},{"key":"2024082420333491900_CIT0027","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/ecco-jcc\/jjac119","article-title":"Systematic review and meta-analysis of peripheral blood DNA methylation studies in inflammatory bowel disease","volume":"17","author":"Joustra","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2024082420333491900_CIT0028","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/cpt.343","article-title":"DNA Methylation of ADME Genes","volume":"99","author":"Fisel","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"2024082420333491900_CIT0029","first-page":"1364","article-title":"Differential DNA methylation correlates with response to methotrexate in rheumatoid arthritis","volume-title":"Rheumatology [Oxford]","author":"Nair","year":"2020"},{"key":"2024082420333491900_CIT0030","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/art.39590","article-title":"Differential methylation as a biomarker of response to etanercept in patients with rheumatoid arthritis","volume":"68","author":"Plant","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2024082420333491900_CIT0031","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/art.41516","article-title":"Multiomics and machine learning accurately predict clinical response to adalimumab and etanercept therapy in patients with rheumatoid arthritis","volume":"73","author":"Tao","year":"2021","journal-title":"Arthritis Rheumatol [Internet]."},{"key":"2024082420333491900_CIT0032","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/bioinformatics\/bty713","article-title":"Bigmelon: tools for analysing large DNA methylation datasets","volume":"35","author":"Gorrie-Stone","year":"2019","journal-title":"Bioinformatics"},{"key":"2024082420333491900_CIT0033","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/bioinformatics\/btu049","article-title":"Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays","volume":"30","author":"Aryee","year":"2014","journal-title":"Bioinformatics"},{"key":"2024082420333491900_CIT0034","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1868-7083-6-4","article-title":"Differences in smoking associated DNA methylation patterns in South Asians and Europeans","volume":"6","author":"Elliott","year":"2014","journal-title":"Clin Epigenetics"},{"issue":"1","key":"2024082420333491900_CIT0035","doi-asserted-by":"crossref","DOI":"10.1186\/s12864-019-5761-7","article-title":"Guidance for DNA methylation studies: statistical insights from the Illumina EPIC array","volume":"20","author":"Mansell","year":"2019","journal-title":"BMC Genomics"},{"key":"2024082420333491900_CIT0036","doi-asserted-by":"crossref","first-page":"e1009443","DOI":"10.1371\/journal.pgen.1009443","article-title":"Assessing the co-variability of DNA methylation across peripheral cells and tissues: Implications for the interpretation of findings in epigenetic epidemiology","volume":"17","author":"Hannon","year":"2021","journal-title":"PLOS Genet"},{"key":"2024082420333491900_CIT0037","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/bioinformatics\/btv560","article-title":"n R package for analyzing data from Illumina\u2019s HumanMethylation450 platform","volume":"32","author":"Phipson","year":"2016","journal-title":"Bioinformatics"},{"key":"2024082420333491900_CIT0038","doi-asserted-by":"crossref","first-page":"41","DOI":"10.12688\/wellcomeopenres.17598.2","article-title":"The EWAS Catalog: a database of epigenome-wide association studies","volume":"7","author":"Battram","year":"2022","journal-title":"Wellcome Open Res"},{"key":"2024082420333491900_CIT0039","first-page":"04.19.23288234","article-title":"Baseline expression of immune gene modules in blood is associated with primary response to anti-TNF therapy in Crohn\u2019s disease patients","volume":"2023","author":"Bai","year":"2023","journal-title":"medRxiv"},{"key":"2024082420333491900_CIT0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2105-13-86","article-title":"DNA methylation arrays as surrogate measures of cell mixture distribution","volume":"13","author":"Houseman","year":"2012","journal-title":"BMC Bioinf"},{"key":"2024082420333491900_CIT0041","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3389\/fimmu.2014.00058","article-title":"SOCS3, a major regulator of infection and inflammation","volume":"5","author":"Carow","year":"2014","journal-title":"Front Immunol"},{"key":"2024082420333491900_CIT0042","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.3389\/fcell.2020.615131","article-title":"Inflammation and Wnt signaling: target for immunomodulatory therapy","volume":"8","author":"Jridi","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"2024082420333491900_CIT0043","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cytogfr.2012.04.005","article-title":"SOCS3 in immune regulation of inflammatory bowel disease and inflammatory bowel disease-related cancer","volume":"23","author":"Li","year":"2012","journal-title":"Cytokine Growth Factor Rev"},{"key":"2024082420333491900_CIT0044","doi-asserted-by":"crossref","first-page":"104053","DOI":"10.1016\/j.ebiom.2022.104053","article-title":"Longitudinal analysis of blood DNA methylation identifies mechanisms of response to tumor necrosis factor inhibitor therapy in rheumatoid arthritis","volume":"80","author":"Juli\u00e0","year":"2022","journal-title":"eBioMed"},{"key":"2024082420333491900_CIT0045","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/ecco-jcc\/jjw053","article-title":"Mechanism of action of anti-TNF therapy in inflammatory bowel disease","volume":"10","author":"Levin","year":"2016","journal-title":"J Crohns Colitis"},{"key":"2024082420333491900_CIT0046","first-page":"1","article-title":"Longitudinal multi-omics analysis identifies early blood-based predictors of anti-TNF therapy response in inflammatory bowel disease","volume":"14","author":"Mishra","year":"2022","journal-title":"Genome"},{"key":"2024082420333491900_CIT0047","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13148-022-01382-9","article-title":"Gene body methylation in cancer: molecular mechanisms and clinical applications","volume":"14","author":"Wang","year":"2022","journal-title":"Clin Epigenetics"},{"key":"2024082420333491900_CIT0048","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.cell.2019.08.008","article-title":"Single-cell analysis of Crohn\u2019s disease lesions identifies a pathogenic cellular module associated with resistance to anti-TNF therapy","volume":"178","author":"Martin","year":"2019","journal-title":"Cell"},{"key":"2024082420333491900_CIT0049","first-page":"11.21.517257","article-title":"Anti-TNF-induced IL-27 modulates regulatory T cell responses in patients with IBD that respond to therapy","volume":"2022","author":"Peres","year":"2022","journal-title":"bioRxiv"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjad133\/51723659\/jjad133.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/18\/8\/1190\/58913383\/jjad133.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/18\/8\/1190\/58913383\/jjad133.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T16:35:06Z","timestamp":1724517306000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/18\/8\/1190\/7238794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,8]]},"references-count":49,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8,8]]},"published-print":{"date-parts":[[2024,8,14]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad133","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.03.22.23287574","asserted-by":"object"}]},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2023,8,8]]}}}